LENZ Therapeutics (LENZ) Cash from Financing Activities (2020 - 2026)
LENZ Therapeutics (LENZ) reported Cash from Financing Activities of $14000.0 for Q1 2026, down 68.18% year-over-year from $44000.0 in Q1 2025, and down 99.99% on a QoQ basis from $122.6 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Cash from Financing Activities data on file, last reported at $14000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 68.18% year-over-year to $14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149.7 million (up 438.97% YoY) and the FY2025 annual result came in at $149.7 million, down 24.75% from the prior year.
- Cash from Financing Activities retreated to $14000.0 in Q1 2026 per LENZ's latest filing, from $122.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $171.3 million in Q1 2024 and bottomed at -$2.1 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is $244000.0 (2022), against an average of $28.7 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities slumped 883.2%; it then surged 231249.06% in 2025.
- Tracing LENZ's Cash from Financing Activities over 5 years: stood at $244000.0 in 2022, then tumbled by 883.2% to -$1.9 million in 2023, then jumped by 102.77% to $53000.0 in 2024, then surged by 231249.06% to $122.6 million in 2025, then slumped by 99.99% to $14000.0 in 2026.
- Per Business Quant, the three latest LENZ Cash from Financing Activities figures stand at $14000.0 (Q1 2026), $122.6 million (Q4 2025), and $598000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 122.62 Mn |
| Dec 31, 2025 | 122.62 Mn |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | 26.49 Mn |
| Jun 30, 2025 | 26.49 Mn |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Sep 30, 2024 | 29.82 Mn |
| Sep 30, 2024 | 29.82 Mn |
| Jun 30, 2024 | -2.14 Mn |
| Jun 30, 2024 | -2.14 Mn |
| Mar 31, 2024 | 171.27 Mn |
| Mar 31, 2024 | 171.27 Mn |
| Dec 31, 2023 | -1.91 Mn |
| Dec 31, 2023 | -1.91 Mn |
| Sep 30, 2023 | -568,000.00 |
| Sep 30, 2023 | -568,000.00 |
| Mar 31, 2023 | 83.18 Mn |
| Mar 31, 2023 | 83.18 Mn |
| Dec 31, 2022 | 244,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Sep 30, 2022 | -59,000.00 |
| Sep 30, 2022 | -59,000.00 |
| Jun 30, 2022 | 412,000.00 |
| Jun 30, 2022 | 412,000.00 |
| Dec 31, 2021 | 313,000.00 |
| Dec 31, 2021 | 313,000.00 |
| Sep 30, 2021 | 31.89 Mn |
| Sep 30, 2021 | 31.89 Mn |
| Jun 30, 2021 | 219.50 Mn |
| Jun 30, 2021 | 219.50 Mn |
| Mar 31, 2021 | 165.77 Mn |
| Mar 31, 2021 | 165.77 Mn |
| Dec 31, 2020 | 15.12 Mn |
| Dec 31, 2020 | 15.12 Mn |
| Sep 30, 2020 | -42,000.00 |
| Sep 30, 2020 | -42,000.00 |